Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: A Surveillance, Epidemiology, and End Results (SEER) analysis -- Dr. Kelly Pendergrass: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC) -- Roger Lyons, M.D.: Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes -- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology Research: Pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation Trial (RDT) -- Guru Sonpavde, M.D.: Sunitinib malate is active and synergistic with cisplatin against human urothelial carcinoma in a preclinical model

About US Oncology Research

The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 528 physicians actively enrolling patients, 82 research sites, and is currently involved in 65 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer- fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About US Oncology, Inc.

US Oncology, headquartered in Houston, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/29/2015)... 2015  Depomed, Inc. (Nasdaq: DEPO ) today ... quarter ended June 30, 2015. "Depomed has ... neurology marketplace, with significant net product revenue growth that ... our shareholders in both the immediate and long term," ... in the second quarter was led by our flagship ...
(Date:7/29/2015)... REDMOND, Washington , 29 luglio 2015 /PRNewswire/ ... tedesco ha scoperto che l,ingestione quotidiana del probiotico ... microbiota intestinale umano e modifica la produzione intestinale ... insulina. Lo studio riguardava la somministrazione quotidiana di ceppo ... ATCC SD-5865) in compresse utilizzando il sistema di ...
(Date:7/29/2015)... July 29, 2015   Turing Pharmaceuticals AG ... joined the company as its first Chief Communication Officer. ... have overall responsibility for internal and external communications and ... He will report directly to Founder and Chairman, ... Leadership Team. "We are excited to have ...
Breaking Medicine Technology:Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 5Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 6Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 7Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 8Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 10Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 11Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 12Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 13Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 14Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 15È stato clinicamente dimostrato che il probiotico L. reuteri di Nutraceutix regola il metabolismo insulinico intestinale 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 3
... Targeted Genetics,Corporation (Nasdaq: TGEN ) announced ... study demonstrate that tgAAC94, its investigational agent,designed to ... mediator of inflammation, is well tolerated and may ... other therapies,including systemic TNF antagonists. Full results of ...
... June 11 /PRNewswire-FirstCall/,-- Iomai Corporation (Nasdaq: IOMI ... company,s positive Phase II field study of its ... analyzed data from 170 travelers,found that those who ... likely to suffer from clinically,significant diarrhea than their ...
Cached Medicine Technology:Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology 2Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology 3Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 2Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 3Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 4Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 5Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 6Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 7
(Date:7/29/2015)... ... 2015 , ... According to the The Media Post on July ... advertisements, for medicinal use are more likely to abuse the substance. A recent study ... is considered beneficial are more apt to use the substance, as opposed to their ...
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - Pipeline ... is a slow, progressive disease that may start in childhood. The report strengthens ... products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the ... expiring November 30, 2019, during its recent meeting. , The Commission received renewal ... program’s compliance with the NCCA’s Standards for the Accreditation of Certification Programs. ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... its name in July to Kalamazoo Strength & Conditioning. , The name change ... “reflects the evolution of our training center over the past three years,” according ...
(Date:7/29/2015)... ... 2015 , ... Today marks a significant achievement in bringing new monies into ... is led by a group of experienced investors, has tapped into an investor community ... to be a part of the fund. The Sofia Fund II is now ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Sofia Fund Surpasses Investor Goals 2
... eases pain in small study, , FRIDAY, July 10 ... helps relieve pain caused by carpal tunnel syndrome, according ... used in Asia, the Middle East, Europe and parts ... by increasing microcirculation, according to researchers at Immanuel Hospital ...
... (APTA) is urging elderly adults who use canes and walkers ... a physical therapist to avoid fall-related injuries. This advice comes ... of the American Geriatrics Society (June 2009), which found ... year due to falls from improper use and fit of ...
... Products Cooperative, Plainview, Minnesota, continues to execute a voluntary ... stabilizers and gums (thickening agents) while making improvements to ... Testing by the U.S. Food and Drug Administration ... affected by the recall has not found any contamination ...
... 10 Hundreds of citizens from Los Gatos, Mountain View ... in front of El Camino Hospital Los Gatos in celebration ... 90-day closure period, El Camino Hospital leaders completed more than ... and physicians, and worked closely with community groups and South ...
... Uganda was the first country in sub-Saharan Africa to register ... however, remains serious as approximately one million Ugandans are HIV ... cost and powerful weapon against new HIV infections: voluntary medical ... and South Africa have demonstrated that male circumcision reduces the ...
... the U.S. Department of Agriculture spent $31 million to ... even though the risk of the disease has been ... decades. Worldwide, especially in developing countries, the disease persists, ... of international trade. The development of new tools ...
Cached Medicine News:Health News:PTs say proper fit and use of walking aids can prevent fall-related injuries in elderly 2Health News:Plainview Milk Products Cooperative Institutes New Policies and Procedures 2Health News:El Camino Hospital Los Gatos Celebrates Opening With the Community 2Health News:El Camino Hospital Los Gatos Celebrates Opening With the Community 3Health News:El Camino Hospital Los Gatos Celebrates Opening With the Community 4Health News:Ugandan Medical Male Circumcision Program Launched to Prevent HIV Transmission 2Health News:Researchers consider herd movements to help eradicate bovine TB 2
... Blood glucose, medication, food, exercise, stress . ... a diabetes patients overall health. Unfortunately, its ... this vital information on a daily basis. ... day-to-day results or submit the information to ...
... The GlucoWatch G2 Biographer is intended ... glucose levels in adults (aged 18 and ... with diabetes. Parents should supervise the use ... The G2 Biographer is intended to supplement, ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Mayo dissecting scissors with beveled blades....
Medicine Products: